DNA Methylation
Gene Expression
Genes, Tumor Suppressor
NOL4
Thyroid Cancer, Papillary
Journal
International journal of endocrinology and metabolism
ISSN: 1726-913X
Titre abrégé: Int J Endocrinol Metab
Pays: Netherlands
ID NLM: 101235597
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
15
08
2020
revised:
08
09
2020
accepted:
19
09
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Thyroid cancer is the fourth most common cancer in the world. Papillary thyroid carcinoma (PTC) accounts for 80% of all types of thyroid neoplasm. Epigenetic alterations such as DNA methylation are known as the main cause of different types of cancers through inactivation of tumor suppressor genes. In the present study, the expression and methylation of suggested gene namely nucleolar protein 4 ( Forty-one patients with PTC and 38 patients affected by MNG were recruited. Thyroid tissues were obtained during thyroidectomy. RNA and DNA were extracted from thyroid tissues. Quantitative RT-PCR assay was performed for determining the mRNA level of Methylation assessment of 81 CpG islands in the promoter region of These data suggested an aberrant promoter hyper-methylation of
Sections du résumé
BACKGROUND
BACKGROUND
Thyroid cancer is the fourth most common cancer in the world. Papillary thyroid carcinoma (PTC) accounts for 80% of all types of thyroid neoplasm. Epigenetic alterations such as DNA methylation are known as the main cause of different types of cancers through inactivation of tumor suppressor genes.
OBJECTIVES
OBJECTIVE
In the present study, the expression and methylation of suggested gene namely nucleolar protein 4 (
METHODS
METHODS
Forty-one patients with PTC and 38 patients affected by MNG were recruited. Thyroid tissues were obtained during thyroidectomy. RNA and DNA were extracted from thyroid tissues. Quantitative RT-PCR assay was performed for determining the mRNA level of
RESULTS
RESULTS
Methylation assessment of 81 CpG islands in the promoter region of
CONCLUSIONS
CONCLUSIONS
These data suggested an aberrant promoter hyper-methylation of
Identifiants
pubmed: 33613681
doi: 10.5812/ijem.108510
pmc: PMC7887463
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e108510Informations de copyright
Copyright © 2020, International Journal of Endocrinology and Metabolism.
Déclaration de conflit d'intérêts
Conflict of Interests: The authors declare no competing interests.
Références
Oncol Rep. 2014 Feb;31(2):1014-20
pubmed: 24337411
Mol Diagn Ther. 2018 Feb;22(1):41-56
pubmed: 28986854
Biomed Res Int. 2019 Dec 28;2019:9379864
pubmed: 31956659
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Anticancer Drugs. 2015 Feb;26(2):187-96
pubmed: 25325304
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Int J Endocrinol Metab. 2018 Feb 10;16(2):e56120
pubmed: 29868127
Shanghai Arch Psychiatry. 2018 Jun 25;30(3):207-212
pubmed: 30858674
Cancer Res. 2008 Apr 1;68(7):2489-97
pubmed: 18381458
Crit Rev Clin Lab Sci. 2016 Aug;53(4):217-27
pubmed: 26678667
PLoS One. 2017 Sep 19;12(9):e0184892
pubmed: 28926589
Asian Pac J Cancer Prev. 2016;17(1):407-12
pubmed: 26838247
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Endocrinol Diabetes Nutr. 2017 Jan;64(1):44-56
pubmed: 28440770
Endocr Relat Cancer. 2019 Jul;26(7):R415-R439
pubmed: 31035251
Biochem Biophys Res Commun. 1998 Nov 9;252(1):97-102
pubmed: 9813152
J Cell Physiol. 2020 Oct;235(10):6954-6968
pubmed: 32017063
Endocrinology. 2007 Mar;148(3):948-53
pubmed: 16946009
Cancer Biomark. 2017;19(2):151-159
pubmed: 28387660
Cancer Genet. 2019 Nov;239:13-21
pubmed: 31472323
J Genet. 2018 Mar;97(1):275-285
pubmed: 29666346